Key result
ACE inhibitors demonstrate an advantage over calcium channel blockers for reducing cardiovascular morbidity and mortality in hypertensive patients.
Why the study?
Do ACE inhibitors reduce cardiovascular morbidity and mortality compared to calcium channel blockers in hypertensive patients?
Do ACE inhibitors reduce cardiovascular morbidity and mortality compared to calcium channel blockers in hypertensive patients?
ACE inhibitors appear superior to CCBs for reducing cardiovascular morbidity and mortality in hypertensive patients, supporting their preferential use in routine therapy.
Answers are grounded in this paper and cite their sources.
ACE inhibitors may be preferred over CCBs for CV outcomes in hypertension; leaves open confirmation by prospective trials.
Large-scale outcome trials have demonstrated that blood pressure reduction with angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs) is associated with reduced cardiovascular complications in hypertension. Comparative trials against conventional drugs and between ACE inhibitors and CCBs have failed to reveal conclusive differences in cause-specific outcomes. Studies in high-risk patients suggest that ACE inhibitors are superior to CCBs and other drugs in protection against cardiovascular events and renal disease. Very long-term prospectively collected observational data from the Glasgow Blood Pressure Clinic and the UK General Practice Research Database strongly support an advantage of ACE inhibitors over CCBs for cardiovascular morbidity and mortality. Considering all the available information, it can be concluded that the use of CCBs in the routine therapy of hypertension cannot be recommended while wider use of ACE inhibitors, along with low-dose diuretics and beta blockers, appears justified.
No takes yet. Share an insight, caveat, or question.
Gordon T. Mclnnes (2003) conducted a review in Hypertension. ACE inhibitors vs. Calcium channel blockers (CCBs) was evaluated on Cardiovascular morbidity and mortality. ACE inhibitors demonstrate an advantage over calcium channel blockers for reducing cardiovascular morbidity and mortality in hypertensive patients.
Synapse has enriched 10 related papers. Consider them for comparative context: